Dear Minister,

Re: Gavi support for Measles Rubella Vaccine Campaign for India

We are writing to inform you that the remaining Measles Rubella Vaccine (MR) campaign operational support of $1.5 million for year 2019 has been approved by Gavi as per the recommendation of the High Level Review Panel on 6 February 2018.

The operational support was granted in response to the request of Government of India to Gavi, the Vaccine Alliance, for technical assistance support from WHO-NPSP and UNICEF for the MR campaign, as per the letters dated 24 May 2017 and 19 September 2017.

We are pleased to share with you a revised Decision Letter to confirm this support. This replaces the letter of 17 November 2017 and states that Gavi has fully approved the requested $8.5 million of MR operational support (line 15).

The operational cost funding has been reallocated from the Rotavirus vaccine support that is part of the $500 million allocation as provided under Annex 6 of the Partnership Framework Agreement (PFA). The funding was reallocated on the basis that firstly, there are savings from the Rotavirus vaccine tender and secondly, that the Government of India will meet any shortfall in funding for Phase 3 of the Rotavirus vaccine introduction from domestic funding, as set out in the letter to Gavi dated 24 May 2017.

The programme budget for vaccine doses remains unchanged. As stated in the previous Decision Letter, the programme budget includes donated doses, in addition to the Gavi commitment of $115 million for MR support. However, please note that in light of the outstanding discussions on Goods and Services Tax (GST) exemption/refunds, $2.4 million have been incurred to date on GSTs levied on previous vaccine deliveries. If the GST cannot be waived or refunded, the total GST would amount to $3.5 million, thereby reducing the volume of support that Gavi will provide, which is noted in the Decision Letter (line 11).

The difference of 3,735,900 doses will have to be financed by the Government of India. We kindly request the Ministry of Health and Family Welfare and the Ministry of Finance to expedite resolution on this matter.
Please note that as per Gavi’s MR Supplemental Immunisation Activities (SIA) reporting requirements, India is requested to provide SIA technical reports on completion of each phase and to conduct a post-campaign coverage survey using WHO’s recently revised coverage survey methodology (line 16).

Finally, we note that the Gavi Board’s decision to provide catalytic support for India’s MR programme is subject to the provisions of Annex 6 of the PFA, in particular the commitments of the Government of India to fund additional costs required as well as scale-up of the programme, and to implement the programme as set out in the approved Performance Framework.

Please do not hesitate to contact the Senior Country Manager for India, Carol Szeto (cszeto@gavi.org), if you have any questions or concerns.

We remain at your disposal for any further enquiry.

Yours sincerely,

Hind Khatib-Othman
Managing Director, Country Programmes

Cc:
PS, The Minister of Health and Family Welfare
PS, The Minister of Finance
Secretary, Ministry of Health and Family Welfare
Additional Secretary, MD NHM, Ministry of Health and Family Welfare
Joint Secretary, Ministry of Health and Family Welfare
Deputy Commissioner (Immunization); MoHFW
Deputy Commissioner (UIP), MoHFW
WHO Country Representative
UNICEF Country Representative
WHO HQ
UNICEF Programme Division
UNICEF Supply Division
India Support for Measles Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme

1. Country: India

2. Grant number: 17-IND-18a-X / 1819-IND-20a-Y

3. Date of Decision Letter: 01 May 2018

4. Date of the Partnership Framework Agreement: 12 June 2015

5. Programme title: NVS, Measles Rubella Campaign

6. Vaccine type: Measles Rubella

7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED

8. Programme duration¹: 2017

9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)

<table>
<thead>
<tr>
<th>Programme Budget Gavi (US$)</th>
<th>2017</th>
<th>Total²</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>US$115,000,000</td>
<td>US$115,000,000</td>
</tr>
<tr>
<td>Programme Budget Gavi - “Donated Doses” (US$)</td>
<td>US$12,341,015</td>
<td>US$12,341,015</td>
</tr>
<tr>
<td>Programme Budget Gavi - TOTAL</td>
<td>US$127,341,015</td>
<td>US$127,341,015</td>
</tr>
</tbody>
</table>

10. Vaccine introduction grant (in US$): Not applicable

11. Indicative annual amounts: (subject to the terms of the Partnership Framework Agreement)³

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2017 - Gavi</th>
<th>2017- Gavi “Donated Doses”</th>
<th>2017 - Gavi TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Measles Rubella vaccines doses</td>
<td>176,923,100*</td>
<td>20,000,000</td>
<td>196,923,100</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$115,000,000</td>
<td>US$12,341,015</td>
<td>US$127,341,015</td>
</tr>
</tbody>
</table>

* Number of doses exclusive of GST amount. If the estimated GST amount of $3,467,399 cannot be refunded for the quantities already delivered and waived for future deliveries, this will reduce the scope of supported doses to 173,187,200, by a difference of 3,735,900.

¹ This is the entire duration of the Programme.
² This is the total amount endorsed by Gavi for the entire duration of the Programme. The Programme budget comprises $115 million as committed to India as part of the India Partnership Strategy (adjusted for budget variance) and $12 million under the donation agreement with the manufacturer. This is based on the current price of the vaccine, as well as taxes and freight costs.
³ This is the amount that Gavi has approved.
12. **Procurement agency**: UNICEF

13. **Self-procurement**: Not applicable

14. **Co-financing obligations**: Not applicable

15. **Operational support for campaigns**:

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Grant amount (US$)</strong></td>
<td>US$7,032,885</td>
<td>US$1,475,135</td>
</tr>
</tbody>
</table>

16. **Additional reporting requirements**: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:

<table>
<thead>
<tr>
<th>Reports and other information</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIA technical report</td>
<td>Within three months of the completion of each phase of the campaign</td>
</tr>
<tr>
<td>Post campaign coverage survey report and actual expenditures report</td>
<td>As soon as available</td>
</tr>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance</td>
<td>To be agreed with Secretariat</td>
</tr>
</tbody>
</table>

17. **Financial clarifications**: Not applicable

18. **Other conditions**: Gavi's catalytic support for India is subject to the provisions in Annex 6 of the Partnership Framework Agreement, and in particular:

- The commitments of the Government of India to provide financing to fund the additional costs required for each programme that is funded with the Partnership Support and to scale up the programmes; and
- Implementation of the programmes in line with the timelines, milestones and indicators set out in the performance framework.

Signed by,

![Signature]

**On behalf of Gavi**

Hind Khatib-Othman  
Managing Director, Country Programmes  
01 May 2018

---

4 UNICEF will not be requested to facilitate the delivery of any "Donated doses".